Delivery Order SPE2DB22D3016-SPE2DB25FBEH6
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Omnipaque 240 mg/ml vials (10 ml units) at a ceiling value of $1,200.00. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 11, 2025, and will be performed at the awardee's location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply needs...
- The Defense Logistics Agency awarded a $1,582.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Omnipaque 180 mg/mL vials (10 mL units) on August 20, 2025, with a completion date of August 21, 2025. This non-set-aside competitive award will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00...
- The Defense Logistics Agency awarded a $5,239.40 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Omnipaque 300 mg/ml in 100ml infusion bottles. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 15, 2025. The contract is performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $1,235.01 to AmerisourceBergen Drug Corp for Omnipaque 300 mg/ml vials (10 ml) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Omnipaque is a contrast medium used in medical imaging procedures, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a $1,622.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for Omnipaque 300 mg/ml infusion bottles (100ml units). The contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 5, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,090.26 to AmerisourceBergen Drug Corp for the supply of Omnipaque 350 mg/ml in 500ml Pluspak units, with an ultimate completion date of November 14, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a single delivery order under AmerisourceBergen's larger contract vehicle with DLA. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $5,036.00 to AmerisourceBergen Drug Corp for the supply of Omnipaque 300 mg/ml vials (10 ml units). This firm fixed-price, competitively awarded contract was executed on October 29, 2025, with an ultimate completion date of October 30, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's extensive...
- The Defense Logistics Agency awarded a delivery order valued at $2,282.49 to AmerisourceBergen Drug Corp for the supply of Omnipaque 300 mg/mL in 100 mL infusion bottles. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with performance based in Conshohocken, Pennsylvania, and an ultimate completion date of September 10, 2025. This delivery order represents a task issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Omnipaque 300 mg/mL infusion bottles (100 mL units) under a firm fixed-price contract valued at $2,183.45. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 9, 2025. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Omnipaque 180 mg/ml vials (10 ml) valued at $3,943.30 under a firm fixed-price contract. The award was made on December 1, 2025, with an ultimate completion date of December 2, 2025. This non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a critical pharmaceutical distributor...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBEH6Delivery Order
The Defense Logistics Agency awarded a $1,044.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Omnipaque 240 mg/ml vials (10 ml) on August 7, 2025, with an ultimate completion date of August 8, 2025. This delivery order is classified as non-set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value transaction typical of the company's extensive portfolio of pharmaceutical product deliveries to federal medical supply chains. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 running through December 2026. As the prime contractor under this IDC, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and medical devices. The company's demonstrated capability to compete successfully for federal pharmaceutical procurement through open competition and its significant market position as a major healthcare solutions provider make it a critical vendor for DLA's medical supply chain supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/7/25 |